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Abstract 
Derisking xenobiotic-induced non-genotoxic carcinogenesis (NGC) represents a 
significant challenge during the safety assessment of chemicals and therapeutic 
drugs. The identification of robust mechanism-based NGC biomarkers has the 
potential to enhance cancer hazard identification. We previously demonstrated 
Constitutive Androstane Receptor (CAR) and WNT signaling-dependent up-
regulation of the pluripotency associated Dlk1-Dio3 imprinted gene cluster non-
coding RNAs (ncRNAs) in the liver of mice treated with tumor-promoting doses of 
phenobarbital (PB). Here, we have compared phenotypic, transcriptional and 
proteomic data from wild-type, CAR/PXR double knock-out and CAR/PXR double 
humanized mice treated with either PB or chlordane, and show that hepatic Dlk1-
Dio3 locus long ncRNAs are upregulated in a CAR/PXR-dependent manner by two 
structurally distinct CAR activators. We further explored the specificity of Dlk1-Dio3 
locus ncRNAs as hepatic NGC biomarkers in mice treated with additional compounds 
working through distinct NGC modes of action. We propose that up-regulation of 
Dlk1-Dio3 cluster ncRNAs can serve as an early biomarker for CAR activator-induced 
non-genotoxic hepatocarcinogenesis and thus may contribute to mechanism-based 
assessments of carcinogenicity risk for chemicals and novel therapeutics.  
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1. Introduction 
Assessing the risk for xenobiotic-induced non-genotoxic carcinogenesis (NGC) is a 
major challenge for safety scientists. This is exemplified by the broad range of cancer 
hazard identification strategies that are selectively deployed during the preclinical 
development of novel therapeutics based on their modality, mode of action, disease 
indication, and phase of development (Moggs et al. 2016). Derisking drug-induced 
carcinogenicity would benefit from the development of reliable mechanism-based 
biomarkers that enable early cancer hazard identification and also enhance 
mechanistic insight for positive tumor findings in life-time rodent carcinogenicity 
studies.  
The liver is a major target organ for xenobiotic-induced NGC. We have used 
Phenobarbital (PB), an anticonvulsant commonly used for treatment of epilepsy and 
other seizures, as a model compound to study mechanisms underlying liver NGC 
mechanisms. PB indirectly activates CAR through molecular pathways that have 
been reported to include the inhibition of epidermal growth factor receptor signaling 
(Mutoh et al. 2013). PB-mediated liver tumor promotion in mice is dependent on CAR 
and β-catenin (Huang et al. 2005; Rignall et al. 2011; Yamamoto et al. 2004). 
Furthermore, β-catenin harbours activating mutations in most CAR-dependent mouse 
liver tumors (Unterberger et al. 2014; Aydinlik et al. 2001). Through integrated 
molecular profiling, we previously uncovered an early, progressive and long-lasting, 
CAR- and β-catenin-dependent up-regulation of the Dlk1-Dio3 imprinted cluster 
ncRNAs in perivenous hepatocytes of mice treated with tumor-promoting doses of PB 
(Lempiainen et al. 2013; Luisier et al. 2014). Several groups have reported a 
potential role for Dlk1-Dio3 derived non-coding transcripts in stem cell pluripotency 
(Liu et al. 2010; Stadtfeld and Hochedlinger 2010). The overexpression of the human 
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Dlk1-Dio3 miRNA cluster was also positively correlated with expression of 
hepatocellular carcinoma (HCC) stem cells markers and was also associated with 
poor survival rate in HCC patients (Luk et al. 2011). Many of the Dlk1-Dio3 cluster 
miRNAs are differentially expressed in hepatocellular carcinomas (Benetatos, 
Vartholomatos, and Hatzimichael 2014; Cui et al. 2015; Xu et al. 2013; Yin et al. 
2013). Together, these observations highlight a pathophysiological role for Dlk1-Dio3 
ncRNA dysregulation in liver cancer and support their functional relevance as early 
NGC biomarkers.  
Xenobiotic-induced activation of CAR and/or Pregnane X receptor (PXR) triggers an 
immediate activation of specific subsets of cytochrome P450 (CYP)-encoding genes, 
including the Cyp2b and Cyp2c family isoforms. CAR and PXR trans-activate a large 
battery of genes involved in phase I oxidation and phase II conjugation pathways that 
contribute to xenobiotic metabolism. PXR and CAR receptors have overlapping 
functions in the regulation of xenobiotic metabolism genes such as Cyp3a, whilst 
CAR- and PXR-specific target genes have also been identified (Cui and Klaassen 
2016; Wei et al. 2002). Chronic CAR activation by PB or other (in)direct activators is 
associated with hepatocellular carcinoma, liver injury, glucose metabolism and 
cholesterol homeostasis (Kobayashi et al. 2015). It was previously proposed that 
monitoring of P450-encoding genes such as Cyp2b10, one of the most strongly 
regulated CAR targets, could provide a robust surrogate biomarker of CAR activation 
in drug-induced mouse liver tumors (Hoflack et al. 2012).  
To explore further the NGC-specificity and CAR-activation dependence of xenobiotic-
induced liver Dlk1-Dio3 long non-coding RNAs (lncRNAs) activation, we compared 
phenotypic, transcriptional and proteomic data from wild-type and CAR/PXR 
transgenic C57BL/6 mouse models following in vivo treatment with PB and the 
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pesticide-derived CAR-activator chlordane (Malarkey 1995; Moser and Smart 1989; 
Ruch et al. 1990). We further investigated selected transcriptional profiles from 
mouse liver samples exposed to additional NGC compounds that work through 
different modes of action (MoA), and show that up-regulation of hepatic Dlk1-Dio3 
cluster non-coding RNAs represents a common feature of CAR-activating 
compounds. Our study highlights Dlk1-Dio3 imprinted cluster lncRNAs as potential 
CAR activator-specific hepatic biomarkers that warrant further evaluation as tools for 
mechanism-based safety assessment of xenobiotic-induced liver non-genotoxic 
carcinogenesis. 
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2. Material and methods  
2.1. Ethics statement  
In vivo mouse studies were performed either according to the Institutional Guidelines 
of the University of Tübingen (Rignall et al. 2011) or in conformity with the Swiss 
Animal Welfare Law -Animal Licenses No. 2345 by “Kantonales Veterinäramt Basel-
Stadt” [Cantonal Veterinary Office, Basel] and No. 5041 by “Kantonales Veterinäramt 
Baselland” [Cantonal Veterinary Office, Basel Land].  
2.2. Animal husbandry and dosing 
For the chlordane in vivo study, eight to eleven week-old male CARh-PXRh, CARKO-
PXRKO and wild-type C57BL/6 mice were used (Taconic, Germany). Animals were 
randomly allocated in groups of 5 per treatment and time point. Mice were checked 
daily for activity and behavior and administered with chlordane (Sigma-Aldrich [St 
Louis, MO] #PS75, 8 mg/kg/day), or corn oil (vehicle) by oral gavage – treatment 
doses were selected based on (Ross et al. 2010; Barrass et al. 1993). After 28 days 
(t=28) of treatment, the compound was withdrawn and the recovery group animals 
kept for a further 28 days for reversibility assessment (t=56). At sacrifice, on day 29 
(2 hrs post-dose) and 57 (recovery period), blood was sampled for pharmacokinetics 
(PK) analysis and hepatic lobes were collected and either frozen in liquid nitrogen 
and stored at −80°C for subsequent analyses or fixed in neutral phosphate-buffered 
formalin and paraffin-embedded (FFPE). To ensure sample homogeneity for different 
molecular profiling methods, frozen liver samples were reduced to powder with 
Covaris Cryoprep system (Covaris Inc., Woburn, MA) and aliquoted on dry ice. For 
the Phenobarbital study comparison, samples from the in vivo study using C57BL/6 
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Wild-type (WT), CAR/PXR double knockout (CARKO-PXRKO) and humanized 
CAR/PXR (CARh-PXRh) mice chronically exposed for 28 days (t=28), 91 days (t=91) 
or 91 days followed by 28 days of recovery (t=119) from (Luisier et al. 2014) were 
analyzed. Additional justification on compounds dose selection is available in 
Supplementary Material and Methods. 
2.3. Cross-compound data mining, Affymetrix labeling, GeneChip 
processing and gene expression analysis 
We performed data mining of in vivo gene expression profiles produced by the 
MARCAR consortium (http://www.imi-marcar.eu/) encompassing six well-known liver 
NGC compounds: Phenobarbital (PB), Pirinixic acid (Wy), Piperonyl Butoxide (PBO), 
1,4-dichlorobenzene (DCB), Cyproterone acetate (CPA), and methapyrilene (Mpy). 
Pioglitazone (Pio) was used as a non-hepatocarcinogen compound and CITCO as a 
human specific CAR activator. Data sets of Wy, PBO, DCB, CPA, MPY, PB, CITCO 
and Pio studies were publically released and available at NCBI’s GEO (GSE68364 
and GSE60684). Affymetrix labeling and GeneChip (Mouse Genome 430 2.0 Array) 
processing were conducted as described in (Lempiainen et al. 2013). Heatmaps were 
built using TIBCO Spotfire®. GeneChip and qPCR expression data analyses were 
described in Supplementary Materials and Methods.   
2.4. RT-qPCR analyses 
RNA isolation and quantitative RT-PCR analyses were performed as previously 
described (Lempiainen et al. 2013) and are detailed in Supplementary Materials and 
Methods. All expression analyses are based on qPCR, primer sequences are 
provided in (Lempiainen et al. 2013) and Supplementary Materials and Methods. 
Data were analyzed using GraphPad Prism 7.0. Statistical significance of treated 
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versus untreated (vehicle) qPCR signal differences (n=5/group) were tested using 
unpaired t-tests with Welch’s correction for unequal variance. 
2.5. Proteomic analysis 
Sample preparation, data acquisition and analysis by targeted high resolution single 
ion monitoring (tHR/SIM) in vivo ‘stable isotope labelling by amino acids in cell 
culture’ (SILAC) using a pathway-enhanced internal standard was carried out as 
described previously (MacLeod et al. 2015) (Supplementary Material and Methods). 
For generation of the hierarchical clustering heatmaps, Xcalibur files were processed 
using MaxQuant, version 1.4.1.2, (Cox and Mann 2008) and the integrated 
Andromeda search engine with the Uniprot Mus musculus (taxID: 10090) reference 
proteome set (44,455 entries, downloaded 03.12.14). Cysteine carbamidomethylation 
was set as a fixed modification, with N-terminal acetylation and methionine oxidation 
as variable modifications. The protein false discovery rate was set to 1%, minimum 
peptide length was 7 and a maximum of 2 miscleavages was allowed. Data were 
processed in Perseus (version 1.5.1.6). For each control/xenobiotic comparison, only 
proteins with ≥3 valid values were retained. Data were analyzed using GraphPad 
Prism 7.0. Statistical significance of treated versus untreated (vehicle) signal 
differences were tested using multiple unpaired t-tests on log2 transformed data. The 
p-values were adjusted using Holm-Sidak method, with alpha = 0.05. 
For proteomics heatmap generation, individual animal data were normalised to the 
mean of the control group, log2-transformed and missing values imputed from normal 
distribution. Clustering was generated in R using the RStudio interface with the gplots 
and RColorBrewer packages. 
2.6. In situ hybridization (ISH) and Immunohistochemistry (IHC) 
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Meg3 in situ hybridization (ISH) and glutamine synthetase (GS) 
immunohistochemistry (IHC) were conducted on liver samples of chlordane- and PB- 
treated animals as previously described (Lempiainen et al. 2013), detailed in 
Supplementary Materials and Methods. 
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3. Results  
3.1. Comparable liver phenotypic and histopathologic responses 
following 28 days in vivo PB and chlordane treatment of mice. 
We previously showed that the Dlk1-Dio3 transcriptional response mediated by PB is 
CAR-dependent (Lempiainen et al. 2013; Luisier et al. 2014). In order to further 
evaluate the specificity of this candidate NGC biomarker for CAR activators, we 
compared the effects of PB and chlordane in the liver of WT, CAR/PXR double 
knockout (CARKO-PXRKO) and double humanized (CARh-PXRh) C57BL/6 animals 
after 28 days (t=28) treatment with either compound (Fig. 1A). Akin to PB, chlordane 
is a NGC compound which induces hepatomegaly characterized by hypertrophy and 
hyperplasia and acts through robust CAR activation (Ross et al. 2010; Barrass et al. 
1993; Malarkey 1995; Whysner et al. 1998).  
No significant body weight differences were observed comparing 28 days PB and 
chlordane treated samples (Table 1). Microscopically, similar histopathological 
changes were observed in liver, characterized by moderate centrilobular 
hepatocellular hypertrophy in WT after 28 days with both treatments. Centrilobular 
hepatocytes showed cytoplasmic changes with an eosinophilic and/or granular 
basophilic cytoplasm in chlordane treated samples (data not shown). Comparable, 
moderate to marked, changes were also made in CARh-PXRh animals. No 
morphological alterations were present in CARKO-PXRKO mice with either compound. 
Following recovery, centrilobular hypertrophy and cytoplasmic changes were still 
present in both WT and CARh-PXRh mice in chlordane- and PB-treated samples, 
although less pronounced in humanized groups.  
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Interestingly, plasma concentration of chlordane-treated samples showed 
appreciable compound levels after 28 days of recovery (t=56, 1 µg/mL in WT 
animals) consistent with chlordane’s long half-life (Zucker 1985). PB on the other 
hand was undetectable after 28 days recovery (t=56) (Table 1). Overall, the liver 
histopathological changes induced by chlordane are CAR/PXR-activation dependent 
and similar to those induced by PB. 
 
3.2. Both chlordane and PB induce Dlk1-Dio3 lncRNA up-regulation in 
perivenous hepatocytes   
We next investigated the transcriptional response of Dlk1-Dio3 lncRNAs in chlordane 
and PB treated mice. Using RT-qPCR, we profiled the expression of both coding and 
long non-coding transcripts throughout the Dlk1-Dio3 cluster in 28-day PB and 
chlordane liver study samples (t=28) (Fig. 1A). The imprinted Dlk1-Dio3 locus 
contains three protein coding genes (Dlk1, Dio3 and Rtl1) expressed from the 
paternally inherited allele, and several maternal-of-origin lncRNAs (Meg3, anti-Rtl1, 
Rian and Mirg) (Benetatos, Vartholomatos, and Hatzimichael 2014) (Fig. 1B). 
Strikingly, PB and chlordane triggered comparable transcriptional activation of Meg3, 
anti-Rtl1, Rian and Mirg lncRNAs in wild-type animals (Fig. 1C) with no detectable 
activation of the coding genes Dlk1 and Dio3. Consistent with long half-life of 
chlordane (Table 1), increased levels of Meg3, anti-Rtl1, Mirg and Cyp2b10 
expression were observed in chlordane (but not PB) recovery group animals (t=56 
and t=119 respectively)  (Supplementary Fig.S1).  
We had previously shown that Meg3 expression occurs within a specific subset of 
perivenous hepatocytes expressing glutamine synthetase (GS) following PB 
treatment (Lempiainen et al. 2013). The Glul gene encoding for the GS protein is a 
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target regulated positively by the WNT signaling pathway and is also expressed in 
PB-promoted tumors (Loeppen et al. 2002). Immunohistochemistry (IHC) and in situ 
hybridization (ISH) directed against GS and Meg3 respectively showed similar Meg3 
lncRNA distribution and no apparent change in GS expression levels with either 
compound in 28-day treated samples (Fig. 1D), altogether consistent with CAR- and 
β-catenin dependence of the Dlk1-Dio3 lncRNAs activation.  
 
3.3. Differential liver Dlk1-Dio3 lncRNA activation in humanized 
CAR/PXR mice following PB versus chlordane exposure  
CAR and PXR double knockouts (CARKO-PXRKO) and double humanized CAR and 
PXR (CARh-PXRh) mouse models were used to examine CAR/PXR dependencies 
and potential species differences in receptor-dependent responses to chlordane (Fig. 
1A). As described previously (Luisier et al. 2014), PB led to comparable activation of 
Dlk1-Dio3 lncRNAs in WT and humanized mice models (approx. 20 fold increase 
over vehicle controls - compare Fig. 2A and Fig. 1C, red bars). In contrast, while 
chlordane treatment led to over 10 fold induction of Dlk1-Dio3 lncRNAs in WT 
animals (Fig. 1C, orange bars), the cluster was minimally induced (approx. 2.5 fold 
induction over control) upon chlordane treatment of CARh-PXRh animals (Fig. 
2A).Consistently, lower levels of Cyp2b10 (Fig. 2C) were also detected in chlordane-
treated CARh-PXRh mice expressing hCAR (Fig. 2D) as compared to WT animals. 
KO animal models showed no Meg3 expression (Fig. 2B) and no detectable 
Cyp2b10 (Fig. 2C) activation upon chlordane treatment, consistent with the 
previously reported CAR dependence of PB effects (Luisier et al. 2014). The 
differential transcriptional responses observed for PB versus chlordane in humanized 
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CAR/PXR mice might be related to distinct, possibly species-specific, mechanisms of 
CAR activation by chlordane.  
 
3.4. Proteome-based analyses of xenobiotic metabolism pathways in 
WT and CARh-PXRh mouse liver following PB and chlordane exposure. 
To further investigate the transcriptomic differences observed in CARh-PXRh animals 
upon chlordane and PB treatments, we next performed peptide quantification using 
stable isotope labelling by amino acids in cell culture (SILAC) analysis of a wide 
range of enzymes implicated in xenobiotic metabolism using liver tissues from WT 
and humanized animals treated for 28 days with PB or chlordane. In WT animal 
samples, we found a comparable pattern of phase I cytochrome P450 protein 
expression following chlordane and PB treatments (Fig. 3). Cyp2b10, one of the 
strongest activated protein targets, showed significantly increased protein expression 
levels following both chlordane and PB treatment (Fig. 3). Selected proteins were 
strongly induced by PB but not by chlordane (e.g. Cyp2c54 and Cyp2c55), or 
inversely were more strongly induced by chlordane than PB (e,g. Por, Ces2a, Gstm3 
and Gstt3), in WT animals (Fig. 3, Supplementary Fig. S3 and S4). Together these 
data suggest that the repertoire of xenobiotic genes activated by both compounds is 
largely but not fully overlapping. It is noteworthy that we also found consistent 
transcriptional and protein level induction in PB-treated WT mice (Supplementary 
Fig. S2). Consistent with the lower Cyp2b10 transcriptional expression in CARh-PXRh 
animals (Fig 2C), we observed reduced levels of a number of measured peptides 
corresponding to Cyp2b10/2b23, Cyp2c55 and Por enzymes in chlordane-treated 
humanized animals (Fig.3, arrowed). Additional Phase I and Phase II enzymes, such 
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as Ces2a and Gstt3 also displayed differential activation by chlordane in the CARh-
PXRh transgenic model (Supplementary Fig. S3 and S4, arrowed), suggesting that 
the humanized CAR model does not conserve the ability to regulate the entire mouse 
repertoire of xenobiotic metabolizing enzymes upon chlordane exposure. Together, 
these results highlight potential differences in chlordane and PB modes of action.   
 
3.5. CAR activator specificity of Dlk1-Dio3 lncRNA upregulation in 
mouse liver 
We next evaluated microarray-based liver transcriptomic profiles derived from mice 
treated with a panel of structurally distinct rodent non-genotoxic carcinogens that 
work through distinct modes of action (studies were conducted Innovative Medicines 
Initiative MARCAR consortium http://www.imi-marcar.eu/; original gene expression 
profiling data available in Gene Expression Omnibus (GEO) under GSE68364 and 
GSE60684). For enhanced comparability, among all studies available, we selected 
data based on (i) study duration, selecting for studies of 28 days and above duration, 
at a stage when Dlk1-Dio3 lncRNAs have been detected unambiguously upon PB 
treatment in B6C3F1 or C57BL/6 mice (Lempiainen et al. 2013; Luisier et al. 2014) 
and (ii) study strain, C57BL/6 studies were chosen to limit the inter-strain variability of 
the response. All available compound studies fulfilling these conditions were selected 
and included one cross-species CAR activator (PB), one human-specific CAR 
activator (CITCO) and five rodent liver NGCs acting through alternative or 
unidentified MoAs (pirinixic acid (WY), piperonyl butoxide (PBO), 1,4-dichloro-
benzene (DCB), cyproterone acetate (CPA) and methapyrilene (MPA)). Pioglitazone 
(Pio), a bladder NGC in male rats, was included as a negative control compound for 
mouse hepatic NGC (detailed in Supplementary Table S1).   
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To compare the CAR activator-dependent effects on xenobiotic metabolism, we 
selected a subset of candidate CAR-dependent target genes involved in phase I and 
II xenobiotic metabolism (based on published CARKO, CARKO-PXRKO animal models 
or on experiments conducted on PB treated hepatocytes - detailed in 
Supplementary Table S2 and references within). While we detected the expected 
CAR-dependent activation of the selected xenobiotic response genes upon PB 
treatment, we also observed activation of Cyb2b10 and other selected xenobiotic 
metabolism genes upon treatment with a range of distinct hepatic NGCs (Fig. 4). 
Specifically, Cyp2b10 expression was strongly regulated by CPA and DCB, and also 
by Pioglitazone (Pio), a PPARγ agonist that we included as a negative control for 
liver NGC (Log2FC from 6.99 to 7.67 for the three compounds, p<0.001, 
Supplementary Table S3). These data indicate that multiple signaling pathways can 
converge to mediate Cyp gene regulation. The CAR dependency of induction of 
Cyp2b and Cyp2c gene expression upon PB treatment was confirmed in CARKO-
PXRKO mice, as previously reported (Kobayashi et al. 2015). 
Among the six rodent hepatic NGCs tested in this experiment, only PB treated liver 
samples showed increased Meg3 and Rian expression (Meg3 Log2FC close to 2 in 
wild-type and humanized models upon 28 and 91 days of PB treatment, absent in 
CARKO-PXRKO animals) (Fig. 4). None of the other five hepatic NGCs led to a 
significant induction of Meg3 or Rian regardless of the mouse strains or durations of  
exposure that were tested. CITCO, a direct and human-specific CAR agonist (Yang 
and Wang 2014), minimally increased the expression of Phase I and Phase II genes 
in CARh-PXRh  samples (Log2FC= 5.94 and 2.72 in CAR
h-PXRh mice, versus 0.69 
and 0.28 in WT for Cyp2b10 and Cyp2c55 respectively), confirming the human 
specificity of CITCO-mediated CAR activation (Fig. 4) (Maglich et al. 2003). 
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However, we did not observe significant transcriptional activation of Meg3 and Rian 
expression levels in humanized CAR/PXR mice under these experimental conditions. 
Taken together, these results suggest that the up-regulaton of Dlk1-Dio3 lncRNA 
expression represents an early biomarker for CAR activator-induced mouse liver 
tumor promotion.  
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4. Discussion  
Non-Genotoxic Carcinogenesis is a key safety assessment consideration for the 
development of chemicals and therapeutic drugs. There are currently no suitable 
short-term assays for predicting NGC. The identification of mechanism-based NGC 
biomarkers would provide industry and regulatory scientists with new tools and 
opportunities for earlier decision-making, mitigation of positive carcinogenicity 
findings and enhanced cancer risk assessment. There are, however, a number of 
significant challenges associated with the identification and application of NGC 
biomarkers (Moggs et al. 2016). Firstly, multiple combinations and chronologies of 
cancer hallmarks contribute to tumorigenicity and thus the detection of individual 
drug-induced neoplastic risk molecular indicators is not likely to be optimal for 
predicting diverse mechanisms of xenobiotic-induced carcinogenesis. Secondly, the 
identification of predictive transcriptomic NGC biomarkers in rodent carcinogenicity 
studies is confounded by the heterogeneity of drug-induced rodent tumors that cover 
a broad range of tissue-, gender-, strain- and species-specific mechanisms. 
Furthermore, the potential contributions from on- or off-target properties of NGC 
compounds makes the determination of mode of action and assessment of human 
relevance very challenging.  
Nevertheless, mechanistic studies that integrate phenotypically-anchored molecular 
and biochemical biomarkers can be used to support the interpretation of drug-
induced tumors and in some cases provide valuable perspectives on potential 
relevance in humans. Although numerous publications report extensive efforts to 
identify predictive transcriptomic biomarkers for NGC, this has proved challenging 
even for a single target organ such as the liver (Kossler et al. 2015; Ellinger-
Ziegelbauer et al. 2011; Fielden et al. 2011). We propose that the validation of such 
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molecular biomarkers will be greatly enhanced by establishing functional 
relationships to known cancer hallmarks. This is exemplified by the identification of 
Dlk1-Dio3 imprinted gene cluster non-coding RNAs as novel candidate biomarkers 
for phenobarbital-induced liver tumor promotion (Lempiainen et al. 2013). The 
induction of Dlk1-Dio3 non-coding RNAs by phenobarbital is dependent on both 
constitutive androstane receptor (CAR) and β-catenin signalling pathways, consistent 
with a CAR activator-mediated hepatocarcinogenesis mode of action. Importantly, 
Dlk1-Dio3 non-coding RNAs have recently been associated with stem cell 
pluripotency in mice and various neoplasms in humans. In addition, the perivenous 
localization of phenobarbital-induced Dlk1-Dio3 non-coding RNAs occurs in a region 
of the liver that was recently associated with Wnt signalling-dependent stem cell-like 
properties (Wang et al. 2015; Planas-Paz et al. 2016). Together, these functional 
relationships imply that sub-population of hepatocytes may be prone to drug-induced 
reprogramming and de-differentiation and that biomarkers such as Dlk1-Dio3 non-
coding RNAs might serve as useful early molecular indicators for CAR-mediated 
hepatocarcinogenesis (Supplementary Figure S5).  
Specifically, in this paper,  we have compared phenotypic, histopathological, 
transcriptional and proteomic responses following treatment with the cross-species 
CAR activators, PB and chlordane, and further compared key transcriptional 
signatures with seven other NGC compounds working through a range of MoAs 
(Supplementary Table S1), including the human-specific direct CAR activator 
CITCO. We find that the xenobiotic metabolism gene Cyp2b10 is upregulated by 
several distinct hepatic NGCs as well as the PPARγ agonist Pioglitazone (a control 
comparator compound that is not associated with hepatic NGC). Although Cyp2b10 
induction in drug-induced mouse liver tumors has previously been proposed as a 
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surrogate biomarker of CAR activation (Hoflack et al. 2012), our data suggest that 
Cyp2b10 induction alone may lack the required specificity for an early mechanism-
based biomarker of CAR-mediated NGC consistent with previous observations that 
induction of CYP2B1/2 liver enzymes failed to correlate with rodent NGC (Elcombe et 
al. 2002). In contrast, our data provide additional support to the CAR activator 
specificity of previously identified Dlk1-Dio3 lncRNA candidate biomarkers for mouse 
liver tumor promotion (Lempiainen et al. 2013).  
Since we used double transgenic (CARKO-PXRKO and CARh-PXRh) animals in the PB 
and chlordane in vivo studies, we cannot formally exclude the role of PXR activation 
and function in the identified molecular signature. CAR shares several common 
features with PXR, and they overlap at a number of target genes and xenobiotic 
activators (Yang and Wang 2014). Although previous studies in CAR and PXR KO 
models also identified differentially regulated xenobiotic targets (Maglich et al. 2002; 
Wei et al. 2002; Cui and Klaassen 2016), the strict specificity to CAR versus PXR 
may require further investigations.  
While both cross-species CAR activators, PB and chlordane, led to Dlk1-Dio3 
lncRNA activation, consistent with its direct human CAR activation MoA (Maglich et 
al. 2003), CITCO did not lead to either xenobiotic genes or Dlk1-Dio3 cluster lncRNA 
activation in WT animals (Fig. 4) and led to moderate Cyp2b10 activation, without 
effect on Dlk1-Dio3 lncRNAs in CAR/PXR humanized animals. The absence of 
lncRNA activation by CITCO is reminiscent of the significantly decreased lncRNA 
activation upon chlordane exposure in humanized animals and could be related to 
species-specific interactions upstream or downstream of CAR/PXR activation that 
could be perturbed in the human transgenic model (Fig. 5). In addition, CITCO acts 
through direct CAR binding and activation, and a conformational change of the hCAR 
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isoforms in transgenic animals might also explain the apparent differences in Cyp 
induction and lack of Dlk1-Dio3 cluster activation. Alternatively, the exposure or 
duration of the study in the transgenic animal studies may not be sufficient to detect 
Dlk1-Dio3 lncRNA activation. Finally, we note that only two long non-coding RNAs 
(Meg3 and Rian) are represented on the microarray used to profile compounds in 
Fig. 4 and thus we cannot exclude that CITCO induces alternate Dlk1-Dio3 ncRNAs. 
Further analyses of the complete Dlk1-Dio3 cluster transcriptional landscape 
following longer-term CITCO treatment in PXRh-CARh animals would be necessary to 
extend these observations as well as to explore the relevance of this compound in 
liver carcinogenesis. Three of the compounds tested (CPA, DCB and Pio), in addition 
to PB and CITCO, led to significant activation of Cyp2b10 and Cyp2c55. However, 
under the experimental conditions tested, they did not induce detectable microarray-
based dysregulation of Dlk1-Dio3 cluster lncRNAs Meg3 or Rian. Interestingly, using 
CYP2B6LacZ reporter and CAR/PXR humanized mouse models, both DCB and CPA 
were recently characterized as CAR activators with DCB displaying a higher potency 
towards human CAR than mouse CAR, and CPA activating both CAR and PXR 
(CJH, CRW, unpublished, manuscript in preparation). While no microarray-based 
upregulation of the Dlk1-Dio3 lncRNAs Meg3 and Rian was detected for either DCB 
or CPA, quantitative PCR-based expression data indicated upregulation of several 
non-coding miRNAs within the Dlk1-Dio3 cluster for both of these compounds 
(unpublished MARCAR data), consistent with our proposal that CAR-activation leads 
to Dlk1-Dio3 cluster ncRNA perturbations in liver NGC models. It is noteworthy that 
the Dlk1-Dio3 cluster encodes one of the largest microRNA clusters in the 
mammalian genome, as well as numerous small nucleolar RNAs (snoRNAs). We 
previously demonstrated PB-mediated induction both lncRNAs and miRNAs from the 
Dlk1-Dio3 locus (Lempiainen et al. 2013). Interestingly, some Dlk1-Dio3 cluster 
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miRNAs appear to be transcribed as single polycistronic unit (Fiore et al. 2009) and 
many of these miRNAs have been reported to be differentially expressed in  
pathologic processes including various cancers (reviewed in (Benetatos et al. 2013)). 
In this manuscript we have evaluated the hepatic responsiveness of four Dlk1-Dio3 
cluster long-non-coding RNAs (Meg3, anti-Rtl1, Rian, Mirg) by qPCR (PB and 
chlordane), and of two Dlk1-Dio3 cluster long-non-coding RNA (Meg3 and Rian) by 
microarray-based transcript profiling (panel of compounds in Fig. 4). We cannot 
exclude that the compounds tested induce further broad or specific changes of the 
Dlk1-Dio3 non-coding RNAs landscape and thus further RNA-sequencing based 
assessments of Dlk1-Dio3 ncRNA candidate biomarkers is warranted. Beyond their 
association with pluripotency (Liu et al. 2010; Stadtfeld and Hochedlinger 2010), the 
interest in investigating the expression profile on the Dlk1-Dio3 cluster lncRNAs, has 
been reinforced by the discovery that they are able to form complexes with the 
epigenetic machinery, including Polycomb group proteins (Kaneko et al. 2014) and 
might be targeted to specific genes through the formation of RNA-DNA triplex 
structures (Mondal et al. 2015). These regulatory interactions (illustrated 
Supplementary Figure S5) could play an important role in cellular transformation.  
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5. Conclusions 
In the present study we have demonstrated that a second CAR activator and mouse 
liver non-genotoxic carcinogen (i.e. chlordane) robustly induces perivenous Dlk1-
Dio3 non-coding RNA expression and we provide preliminary evidence that this 
candidate biomarker signature may indeed be specific for CAR-mediated 
hepatocarcinogenesis. Through comparing the response to chlordane and PB 
exposure in WT and humanized animals, we also point to the existence of 
undetermined co-effector phenomenon, upstream or downstream to CAR activation 
(Fig. 5). Since significant molecular, cellular and pathophysiologic differences exist 
between mammalian species and strains, further evaluation of Dlk1-Dio3 cluster non-
coding RNA functions, biomarker detection sensitivity, MoA specificity and human 
relevance, is warranted prior to use as an early indicator for CAR-mediated 
hepatocarcinogenesis. In particular, mapping species differences in the hepatic 
chromatin architecture of candidate non-genotoxic carcinogen effector genes such as 
Dlk1-Dio3 ncRNAs may help predict the potential for NGC-mediated modulation in 
humans (AV, RT and JM, unpublished data).   
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Figure Legends 
Figure 1. Dlk1-Dio3 cluster response upon 28 days phenobarbital or chlordane 
exposure. (A) Experimental design of the chlordane and PB studies for molecular 
and phenotypic profiling (B) Architecture of Dlk1-Dio3 genomic region illustrating 
parent-of-origin transcripts and differentially methylated regions (DMR) – methylated 
regions are represented with solid circles. (C) RT-qPCR analysis of Dlk1-Dio3 genes 
(Dlk1 and Dio3) and long non-coding RNAs (Meg3, anti-Rtl1, Rian, Mirg) expression 
in wild type (WT) mouse livers treated for 28 days with PB, chlordane or the relevant 
vehicle controls. Expression levels are indicated as mean ± SEM (n=5 biological 
replicates/group). Data were analyzed using GraphPad Prism 7.0. Statistical 
significance of treated versus untreated (vehicle) qPCR signal differences were 
tested using unpaired t-tests with Welch’s correction for unequal variance, *p<0.05, 
**p<0.01. (D) Meg3 in situ hybridization and GS immunohistochemistry in 28 days PB 
or in chlordane treated livers with indicated vehicle controls. Water (H2O), Corn Oil 
(CO). 
Figure 2. Dlk1-Dio3 cluster lncRNAs are differentially induced by PB and 
chlordane in humanized CAR/PXR animals. (A) Dlk1-Dio3 coding and non-coding 
RNAs expression analysis in CARh-PXRh mice after 28 days chlordane or PB 
exposure (t=28d), in comparison to indicated vehicle control treatments. (B) Meg3 
expression analysis in WT and CARKO/PXRKO mice after 28 days of chlordane 
treatment (t=28d) as compared to vehicle treated samples. (C) Cyp2b10 expression 
analyses across indicated mouse models after 28 days PB or chlordane treatment 
(t=28d). (D) human CAR (hCAR) expression analysis across indicated mouse models 
after 28 days of treatments (t=28d). Expression levels are indicated as mean ± SEM 
(n=5 biological replicates/group). Data were analyzed using GraphPad Prism 7.0.  All 
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expression analyses are based on qPCR, primer sequences are provided in 
(Lempiainen et al. 2013) and Supplementary Materials and Methods. Statistical 
significance of treated versus untreated (vehicle) qPCR signal differences were 
tested using unpaired t-tests with Welch’s correction for unequal variance, *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. Vehicle controls: Water (H2O) and Corn Oil 
(CO). 
 
Figure 3. Proteomic analysis of Phase I cytochrome P450 (Cyp) expression in 
WT and CARh PXRh mice. Quantitative measurement of peptides using in vivo 
‘stable isotope labeling with amino acids in cell culture’ (SILAC) technique from PB 
treated (A) and chlordane treated (B) liver samples, in comparison with indicated 
vehicle controls, in WT (filled bars) and in CARh/PXRh (hatched bars) mice after 28 
days of treatment (t=28d). Corresponding proteins are named on the X axis; the Y 
axis is expressed in fold change expression, based of vehicle expression value. 
Arrows indicate the metabolic enzymes concerned by the decreased signal in 
chlordane treated CARh/PXRh samples as compared to WT samples. Protein levels 
are indicated as mean ± SEM (H2O and phenobarbital n=5 biological 
replicates/group; CO and Chlordane n=3 biological replicates/group). Data were 
analyzed using GraphPad Prism 7.0.  Statistical significance of treated versus 
untreated (vehicle) signal differences were tested using multiple unpaired t-tests on 
log2 transformed data.   The p-values were adjusted using Holm-Sidak method, 
*p<0.05, **p<0.01, ***p<0.001. Vehicle controls: Water (H2O) and Corn Oil (CO) 
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Figure 4. Cross-compound comparison of microarray-based xenobiotic 
metabolism and Dlk1-Dio3 lncRNAs transcriptional expression profiles. In vivo 
study samples from indicated compound classes were profiled by Affymetrix 
microarray and specific gene expression signatures (phase I and phase II xenobiotic 
genes and progressive Dlk1-Dio3 encoded Meg3 lncRNA expression) extracted and 
compared. Probes set expression values were summarized by gene and expressed 
in Log2 fold change (Log2FC) expression, calculated on the average of the 5 
replicates (treated versus control). Significant difference between vehicle and treated 
conditions were tested with the limma package with the Benjamini-Hochberg method 
correction applied (Klipper-Aurbach et al. 1995; Smyth, Michaud, and Scott 2005), 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. NGC: Non-genotoxic carcinogen, NC: 
non-carcinogen, CPA: cyproterone acetate, DCB: 1,4-dichlorobenzene, Mpy: 
Methapyrilene, PB: phenobarbital, PBO: piperonyl butoxide, Wy: pirinixic acid, Pio: 
pioglitazone. 
 
Figure 5. Updated model for NGC-induced pertrubation of the Dlk1-Dio3 cluster 
lncRNA and xenobiotic response (modified from (Lempiainen et al. 2013)). Direct 
CAR activators or indirect compounds acting through cellular transducers (green 
triangle, e.g. as described in (Mutoh et al. 2013)) regulate the expression of CAR-
dependent xenobiotic genes. The β-catenin pathway regulates expression of 
xenobiotic metabolic genes in a context dependent manner (Braeuning et al. 2009). 
Within WNT positive domains (e.g. perivenous hepatocytes) CAR activation is also 
associated with Dlk1-Dio3 cluster ncRNAs expression. The current model 
acknowledges the presence of intermediate/uncharacterized co-effectors (orange 
hexagons) acting downstream CAR activation, and possibly linking the constitutive 
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xenobiotic metabolism and the progressive CAR/β-catenin dependent response. The 
upregulation of Dlk1-Dio3 cluster ncRNAs might contribute to hepatocyte hypertrophy 
and reprogramming (Luk et al. 2011), while xenobiotic response may lead to 
oxidative stress through the production of reactive metabolites (Omura et al. 2014), 
both contributing potential key events in drug-induced tumor promotion. 
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Supplementary Figure legends  
Supplementary Figure S1. RT-qPCR analyses of Dlk1-Dio3 cluster and Cyp2b10 
gene expression following 28 day compound withdrawal. Gene expression 
measurement of (A) Dlk1-Dio3 coding (Dlk1 and Dio3) and non-coding RNAs (Meg3, 
anti-Rtl1, Rian, Mirg) and (B) Cyp2b10 after treatment regimen (t=91 days in H2O-
phenobarbital study and t=28 days in CO-chlordane study) followed by 28 days of 
compound withdrawal (t=119 and t=56 days respectively). Expression levels are 
indicated as mean ± SEM (n=5 biological replicates/group). Data were analyzed 
using GraphPad Prism 7.0.  Statistical significance of treated versus untreated 
(vehicle) qPCR signal differences were tested using unpaired t-tests with Welch’s 
correction for unequal variance, *p<0.05, **p<0.01, ***p<0.001. Vehicle controls: 
Water (H2O) and Corn Oil (CO). 
 
Supplementary Figure S2. Proteomics and gene expression profiles 
comparison of a panel of PB-responsive xenobiotic metabolism proteins. 
Probes set expression values were summarized by (A) gene, and (B) protein 
expression, deducted from SILAC peptide measurement, are expressed in log2 fold 
change (Log2FC) expression, calculated on the average of the 5 replicates (treated 
versus control). Vh_1016 to Vh_1020 and WT_V1 to WT_V5 correspond to vehicle 
treated samples, PB_2016 to PB_2020 and WT_PB1 to WT_PB5 correspond to 
Phenobarbital treated samples for gene expression and protein expression analyses 
respectively. Hierarchical clustering was performed for individual animal group and 
gene/protein expression. 
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Supplementary Figure S3. Proteomics analysis of non-Cyp phase I protein 
expression in WT and CARh PXRh mice. Quantitative measurement of peptides 
using the ‘stable isotope labeling with amino acids in cell culture’ (SILAC) technique 
from (A) PB treated and (B) chlordane treated liver samples, in WT (filled bars) and in 
CARh PXRh (hatched bars) mice. Corresponding proteins are named on the X axis; 
the Y axis is expressed in fold change expression, based of vehicle expression value. 
Arrows indicate the metabolic enzymes concerned by the decreased signal in 
chlordane treated CARh/PXRh samples as compared to WT samples. Protein levels 
are indicated as mean ± SEM (H2O and phenobarbital n=5 biological 
replicates/group; CO and Chlordane n=3 biological replicates/group).Data were 
analyzed using GraphPad Prism 7.0. Statistical significance of treated versus 
untreated (vehicle) signal differences were tested using multiple unpaired t-tests on 
log2 transformed data. The p-values were adjusted using Holm-Sidak method, 
*p<0.05, **p<0.01. Vehicle controls: Water (H2O) and Corn Oil (CO). 
 
Supplementary Figure S4. Proteomics analysis of phase II protein expression 
in WT and CARh PXRh mice. Quantitative measurement of peptides using the in 
vivo ‘stable isotope labeling with amino acids in cell culture’ (SILAC) technique from 
(A) PB treated and (B) chlordane treated liver samples, in WT (filled bars) and in 
CARh PXRh (hatched bars) mice. Corresponding proteins are named on the X axis; 
the Y axis is expressed in fold change expression, based of vehicle expression value. 
Protein levels are indicated as mean ± SEM (H2O and phenobarbital n=5 biological 
replicates/group; CO and Chlordane n=3 biological replicates/group). Data were 
analyzed using GraphPad Prism 7.0. Statistical significance of treated versus 
untreated (vehicle) signal differences were tested using multiple unpaired t-tests on 
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log2 transformed data. The p-values were adjusted using Holm-Sidak method, 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Vehicle controls: Water (H2O) and Corn 
Oil (CO). 
Supplementary Figure S5. Role of Dlk1-Dio3 non-coding RNAs in liver cancer 
and their potential relevance as non-genotoxic carcinogenesis biomarkers. (A) 
The potential relevance of mechanisms of drug-induced tumors in humans is 
frequently investigated by integrating tissue histopathology and biochemical and 
molecular indicators of neoplastic risk. Mechanistic studies that integrate 
phenotypically-anchored molecular and biochemical biomarkers have the potential to 
provide mechanistic insights to help evaluate early on the risk for drug induced 
carcinogenesis, as well as support the interpretation of drug-induced tumors and in 
some cases provide valuable perspectives on potential relevance in humans (Moggs 
et al. 2016). (B) Phenobarbital case study exemplifying the identification of Dlk1-Dio3 
imprinted gene cluster noncoding RNAs as novel candidate biomarkers for 
phenobarbital-induced liver tumor promotion (Lempiainen et al. 2013). Pathway 
dependence (CAR and β-catenin) and phenotypic anchoring (e.g. tissue localization, 
phenotype), represent important steps of the candidate biomarker characterization. 
(C) Deregulation of the Dlk1-Dio3 cluster was observed in numerous developmental 
disorders and neoplasia, including hepatocellular carcinoma in humans and in mouse 
models. Dlk1-Dio3 associated non-coding RNA (including Meg3) genetically and 
biochemically interact and regulate a number of important cellular processes whose 
deregulation may be critical for tumor promotion and progression.  snoRNA, small 
nucleolus RNA. 
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Supplementary Table legends 
Supplementary Table S1. List of model compounds and associated study 
designs. The compound class, known mechanism of action, link to CAR dependency 
and a summary of the in vivo experimental conditions are shown. GC: genotoxic 
carcinogenesis, NGC: non genotoxic carcinogenesis, CMC: carboxy-methyl cellulose, 
po: oral intake, ip: intraperitoneal injection.  
Supplementary Table S2. List of selected xenobiotic metabolism genes, 
representing candidate CAR-activation dependent signature.  The original study 
design contributing to the identification of the selected genes is indicated.   po: oral 
intake, ip: intraperitoneal injection.  
Supplementary Table S3. Microarray data of selected xenobiotic metabolism 
genes and Dlk1-Dio3 cluster ncRNAs. The table indicates RMA-normalized and 
summarized by gene Log2FC between treated and vehicle samples and adjusted p-
values using the Benjamini-Hochberg method. The study ID indicates the key study 
and compound information. The drug, genetic background and time of treatment are 
indicated.  
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Tables 
Table 1.  Phenobarbital and chlordane lead to comparable liver phenotype in vivo. Toxicological and pathological data after 28 
days (t=28) chlordane and 28 (t=28) or 91 (t=91) days PB treatment (Main) are shown. Recovery (Rec) was run for an additional 28 
days for the chlordane and phenobarbital studies (t=56 and t=119 respectively). Body weight and plasma concentrations are indicated 
as mean value of indicated (n) individuals per group ± standard deviation. In vivo data referring to the phenobarbital study are adapted 
from (Luisier et al. 2014). Centrilobular hypertrophy severity grades were on a 0-4 scale, expressed as median (n=5).  
 
phenobarbital chlordane 
 
wild - type CAR
h 
– PXR
h
 CAR
KO 
- PXR
KO
 wild - type CAR
h 
– PXR
h
 CAR
KO 
- PXR
KO
 
 
Main 
t=28 
Main 
t=91 
Rec 
t=119 
Main 
t=28 
Main 
t=91 
Rec 
T=119 
Main 
t=28 
Main 
t=91 
Rec 
t=119 
Main 
t=28 
Rec 
t=56 
Main 
t=28 
Rec 
t=56 
Main 
t=28 
Rec 
t=56 
Body weight 
 
27.6 
± 2.2 
n=15 
33.9 
±  2.8 
n=10 
33.1 
±  1.7 
n=5 
26.5 
± 1.3 
n=15 
31.0 
± 2.5 
n=10 
31.3 
±  2.4 
n=5 
27.8 
± 2.1 
n=15 
31.5 
± 4.7 
n=10 
30.6 
± 4.4 
n=5 
24.6 
± 1.2 
n=10 
26.2 
±  2.4 
n=5 
25.5 
± 1.8 
n=10 
23.77 
± 1.1 
n=5 
25.3 
± 1.3 
n=10 
25.6 
± 0.8 
n=5 
Plasma 
concentration 
(μg/mL) n=5 
 
19.7 
± 3.6 
11.1 
± 3.2 
0.0 
±  0.0 
32.3 
± 5.2 
17.0 
± 7.2 
0.0 
± 0.0 
82.7 
±  8.9 
52.6 
± 6.3 
0.0 
±  0.0 
7.7 
± 3.5 
1.0 
± 0.4 
4.8 
± 1.2 
2.3 
±  2.0 
5.2 
± 2.0 
2.1 
± 1.3 
Centrilobular 
hypertrophy 
(score 0:4) 
Median 
2 3 2 3 3 1 0 1 0 3 2 3 2 0 0 
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Luisier, R., H. Lempiainen, N. Scherbichler, A. Braeuning, M. Geissler, V. Dubost, A. Muller, N. Scheer, S. D. Chibout, H. Hara, F. 
Picard, D. Theil, P. Couttet, A. Vitobello, O. Grenet, B. Grasl-Kraupp, H. Ellinger-Ziegelbauer, J. P. Thomson, R. R. Meehan, C. 
R. Elcombe, C. J. Henderson, C. R. Wolf, M. Schwarz, P. Moulin, R. Terranova, and J. G. Moggs. 2014. 'Phenobarbital induces 
cell cycle transcriptional responses in mouse liver humanized for constitutive androstane and pregnane x receptors', Toxicol 
Sci, 139: 501-11. 
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Figure 3. Pouché, Vitobello et al.
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